Table 3.

Magnitude of Improvement in Use of Evidence‐Based Heart Failure Therapies From Baseline to 24 Months by Type of Medical Record System^a

				Univariate Analysis				Multivariate Analysis
	Improvement in Use of Therapy by EHR Group (Absolute Rate, Unadjusted), %			EHR‐Always vs Paper‐Always		EHR‐Switched vs Paper‐Always		EHR‐Always vs Paper‐Always		EHR‐Switched vs Paper‐Always
Quality Measure	EHR‐Always %	EHR‐Switched %	Paper‐Always %	Unadjusted OR (95% CI)	P	Unadjusted OR (95% CI)	P	Adjusted OR (95% CI)	P	Adjusted OR (95% CI)	P
ACEI/ARB	7.3	9.3	8.6	0.83 (0.64–1.07)	0.1538	1.03 (0.68–1.55)	0.8907	0.83 (0.63–1.09)	0.1835	1.02 (0.66–1.57)	0.9415
β‐Blocker	6.9	7.7	5.3	1.24 (0.90–1.69)	0.1837	1.30 (0.79–2.15)	0.3063	1.43 (1.05–1.93)	0.0225	1.65 (1.00–2.74)	0.0506
Aldosterone antagonist	17.4	27.8	20.7	0.83 (0.55–1.25)	0.3673	1.45 (0.65–3.27)	0.3642	0.86 (0.49–1.50)	0.5893	0.97 (0.36–2.61)	0.9490
Anticoagulation for atrial fibrillation	6.4	4.9	8.6	0.71 (0.50–1.01)	0.0551	0.53 (0.31–0.92)	0.0247	0.65 (0.40–1.05)	0.0795	0.73 (0.35–1.54)	0.4105
Implantable cardioverter‐defibrillator	19.1	16.3	18.0	1.09 (0.87–1.36)	0.4467	0.82 (0.56–1.22)	0.3341	1.06 (0.78–1.44)	0.6936	0.67 (0.42–1.07)	0.0901
Cardiac resynchronization therapy	33.6	41.7	31.1	1.15 (0.69–1.92)	0.5889	1.60 (0.63–4.09)	0.3275	1.33 (0.73–2.43)	0.3527	0.81 (0.26–2.53)	0.7199
HF education	24.7	31.4	26.6	0.83 (0.60–1.15)	0.2606	1.31 (0.86–2.00)	0.2074	0.95 (0.67–1.35)	0.7888	1.40 (0.88–2.22)	0.1532

Abbreviations: ACEI/ARB, angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker; CI, confidence interval; EHR, electronic health record system; HF, heart failure; OR, odds ratio.

^aImprovement for each quality measure was defined as new treatment at 24 months of patients who were eligible for the quality measure at both time points but who were not treated at baseline. Patients who were ineligible at either time point were excluded.